<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurosci</journal-id><journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1662-4548</issn><issn pub-type="epub">1662-453X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6037894</article-id><article-id pub-id-type="doi">10.3389/fnins.2018.00440</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neuroscience</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Chemical Proteomic Analysis of Serine Hydrolase Activity in Niemann-Pick Type C Mouse Brain </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van Rooden</surname><given-names>Eva J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/530058/overview"/></contrib><contrib contrib-type="author"><name><surname>van Esbroeck</surname><given-names>Annelot C. M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Baggelaar</surname><given-names>Marc P.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/550741/overview"/></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Florea</surname><given-names>Bogdan I.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marques</surname><given-names>André R. A.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/574167/overview"/></contrib><contrib contrib-type="author"><name><surname>Ottenhoff</surname><given-names>Roelof</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Boot</surname><given-names>Rolf G.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/449327/overview"/></contrib><contrib contrib-type="author"><name><surname>Overkleeft</surname><given-names>Herman S.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Aerts</surname><given-names>Johannes M. F. G.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/437003/overview"/></contrib><contrib contrib-type="author"><name><surname>van der Stelt</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/123891/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Molecular Physiology, Leiden Institute of Chemistry, Leiden University</institution>, <addr-line>Leiden</addr-line>, <country>Netherlands</country></aff><aff id="aff2"><sup>2</sup><institution>Bioorganic Synthesis, Leiden Institute of Chemistry, Leiden University</institution>, <addr-line>Leiden</addr-line>, <country>Netherlands</country></aff><aff id="aff3"><sup>3</sup><institution>Institute of Biochemistry, Christian-Albrechts-Universität zu Kiel</institution>, <addr-line>Kiel</addr-line>, <country>Germany</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country>Netherlands</country></aff><aff id="aff5"><sup>5</sup><institution>Medical Biochemistry, Leiden Institute of Chemistry, Leiden University</institution>, <addr-line>Leiden</addr-line>, <country>Netherlands</country></aff><author-notes><fn fn-type="edited-by"><p><text><SENT sid="1" pm="."><plain>Edited by: Carsten T. </plain></SENT>
<SENT sid="2" pm="."><plain>Wotjak, Max-Planck-Institut für Psychiatrie, Germany </plain></SENT>
</text></p></fn><fn fn-type="edited-by"><p><text><SENT sid="3" pm="."><plain>Reviewed by: Beat Lutz, Johannes Gutenberg-Universität Mainz, Germany; Sulev Kõks, University of Tartu, Estonia </plain></SENT>
</text></p></fn><corresp id="c001">*Correspondence: Mario van der Stelt, <email>m.van.der.stelt@chem.leidenuniv.nl</email></corresp><fn fn-type="other" id="fn002"><p><text><SENT sid="4" pm="."><plain>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="epub"><day>03</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>12</volume><elocation-id>440</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>11</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement>Copyright © 2018 van Rooden, van Esbroeck, Baggelaar, Deng, Florea, Marques, Ottenhoff, Boot, Overkleeft, Aerts and van der Stelt.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>van Rooden, van Esbroeck, Baggelaar, Deng, Florea, Marques, Ottenhoff, Boot, Overkleeft, Aerts and van der Stelt</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>The endocannabinoid system (ECS) is considered to be an endogenous protective system in various neurodegenerative diseases. </plain></SENT>
<SENT sid="6" pm="."><plain>Niemann-Pick type C (NPC) is a neurodegenerative disease in which the role of the ECS has not been studied yet. </plain></SENT>
<SENT sid="7" pm="."><plain>Most of the endocannabinoid enzymes are serine hydrolases, which can be studied using activity-based protein profiling (ABPP). </plain></SENT>
<SENT sid="8" pm="."><plain>Here, we report the serine hydrolase activity in brain proteomes of a NPC mouse model as measured by ABPP. </plain></SENT>
<SENT sid="9" pm="."><plain>Two ABPP methods are used: a gel-based method and a chemical proteomics method. </plain></SENT>
<SENT sid="10" pm="."><plain>The activities of the following endocannabinoid enzymes were quantified: diacylglycerol lipase (DAGL) α, α/β-hydrolase domain-containing protein 4, α/β-hydrolase domain-containing protein 6, α/β-hydrolase domain-containing protein 12, fatty acid amide hydrolase, and monoacylglycerol lipase. </plain></SENT>
<SENT sid="11" pm="."><plain>Using the gel-based method, two bands were observed for DAGL α. </plain></SENT>
<SENT sid="12" pm="."><plain>Only the upper band corresponding to this enzyme was significantly decreased in the NPC mouse model. </plain></SENT>
<SENT sid="13" pm="."><plain>Chemical proteomics showed that three lysosomal serine hydrolase activities (retinoid-inducible serine carboxypeptidase, cathepsin A, and palmitoyl-protein thioesterase 1) were increased in Niemann-Pick C1 protein knockout mouse brain compared to wild-type brain, whereas no difference in endocannabinoid hydrolase activity was observed. </plain></SENT>
<SENT sid="14" pm="."><plain>We conclude that these targets might be interesting therapeutic targets for future validation studies. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>chemical proteomics</kwd><kwd>activity-based protein profiling</kwd><kwd>endocannabinoid system</kwd><kwd>hydrolases</kwd><kwd>Niemann-Pick type C</kwd></kwd-group></SecTag><counts><fig-count count="3"/><table-count count="1"/><equation-count count="0"/><ref-count count="44"/><page-count count="9"/><word-count count="0"/></counts></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="15" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="16" pm="."><plain>The endocannabinoid system (ECS) consists of the cannabinoid type 1 and 2 receptors (CB1R and CB2R) and their endogenous ligands: the endocannabinoids. </plain></SENT>
<SENT sid="17" pm="."><plain>The lipids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the best characterized endocannabinoids (Di Marzo et al., 2004). </plain></SENT>
<SENT sid="18" pm="."><plain>The enzymes responsible for endocannabinoid biosynthesis and degradation are also part of the ECS, with most endocannabinoid degrading enzymes belonging to the serine hydrolase family (Figure 1; Blankman and Cravatt, 2013). </plain></SENT>
<SENT sid="19" pm="."><plain>The combined activities of biosynthetic enzymes and degradative enzymes tightly regulate endocannabinoid concentrations in the brain. </plain></SENT>
<SENT sid="20" pm="."><plain>For example, 2-AG is mainly produced from 1-acyl-2-AG by the diacylglycerol lipases (DAGLs), DAGLα and DAGLβ, while it is degraded by monoacylglycerol lipase (MAGL) and to a minor extent by α,β-hydrolase domain-containing protein 6 (ABHD6) and α,β-hydrolase domain-containing protein 12 (ABHD12). </plain></SENT>
<SENT sid="21" pm="."><plain>Multiple pathways are known for the biosynthesis of AEA, but they all use N-acylphospatidylethanolamine (NAPE) as a central precursor, including the serine hydrolase α,β-hydrolase domain-containing protein 4 (ABHD4) and the β-metallolactamase N-acylphospatidylethanolamine-phospholipase D (NAPE-PLD). </plain></SENT>
<SENT sid="22" pm="."><plain>NAPE is synthesized by the calcium-dependent N-acyltransferase phospholipase A2 group 4E (PLA2G4E) (Ogura et al., 2016). </plain></SENT>
<SENT sid="23" pm="."><plain>Fatty acid amide hydrolase (FAAH) terminates AEA signaling by hydrolysis of its amide bond. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" position="float"><label>FIGURE 1</label><caption><p><text><SENT sid="24" pm="."><plain>Pathways for the biosynthesis and degradation of the endocannabinoids 2-AG and AEA. </plain></SENT>
<SENT sid="25" pm="."><plain>Enzymes with known activity-based probes are underlined. </plain></SENT>
<SENT sid="26" pm="."><plain>R1/R2, alkyl chains, R3, arachidonoyl. </plain></SENT>
<SENT sid="27" pm="."><plain>ABHD, α/β-hydrolase domain-containing protein; AEA, anandamide; 2-AG: 2-arachidonoylglycerol; DAG, diacylglycerol; DAGL, diacylglycerol lipase; FAAH, fatty acid amide hydrolase; GDE1, glycerophosphodiesterase 1; LPC, lysophosphatidylcholine; MAGL, monoacylglycerol lipase; NAPE, N-acylphosphatidylethanolamine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PIP2, phosphatidylinositol 4,5-bisphosphate; PLA2G4E, phospholipase A2 group 4E; PLC, phospholipase C; PLD, phospholipase D. </plain></SENT>
</text></p></caption><graphic xlink:href="fnins-12-00440-g001"/></fig></SecTag><p><text><SENT sid="28" pm="."><plain>Endocannabinoid hydrolases that are part of the serine hydrolase superfamily can be studied using activity-based protein profiling (ABPP), a method which uses chemical probes for measuring enzyme activity in complex biological samples. </plain></SENT>
<SENT sid="29" pm="."><plain>Previously, we have used ABPP to compare serine hydrolase activity in wild-type and CB1R knockout mice (Baggelaar et al., 2017). </plain></SENT>
<SENT sid="30" pm="."><plain>Comparative ABPP has also been successfully applied in the identification of new drug targets (Nomura et al., 2010a,b). </plain></SENT>
<SENT sid="31" pm="."><plain>With ABPP, enzyme activities that are deregulated in a certain pathophysiological state can be identified and the relative amount of active enzyme copies as compared to wild-type situations quantified. </plain></SENT>
<SENT sid="32" pm="."><plain>The classical fluorophosphonate (FP)-based probes (FP-TAMRA and FP-biotin; Liu et al., 1999) act as broad-spectrum serine hydrolase probes that label the endocannabinoid enzymes FAAH, MAGL, PLA2G4E (Ogura et al., 2016), ABHD6, and ABHD4 (Liu et al., 1999; Simon and Cravatt, 2010), whereas the tailor-made tetrahydrolipstatin (THL)-based probes (MB064 and MB108) label both DAGL isoforms (alpha and beta) and ABHD4, ABHD6, and ABHD12 (Baggelaar et al., 2013, 2015, 2017; Ogasawara et al., 2016). </plain></SENT>
<SENT sid="33" pm="."><plain>Of note, the fluorescent probe DH379 (Ogasawara et al., 2016) selectively targets DAGL and ABHD6 (Supplementary Figure S1). </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>Evaluation of endocannabinoid hydrolase activity in native tissue may provide insight in the role of the ECS in physiological and disease processes. </plain></SENT>
<SENT sid="35" pm="."><plain>Interestingly, endocannabinoid levels are elevated during neurodegeneration and neuroinflammation (van der Stelt and Di Marzo, 2005; Nomura et al., 2011; Chiurchiù et al., 2017). </plain></SENT>
<SENT sid="36" pm="."><plain>For example, endocannabinoid signaling is perturbed in various animal models of neurodegenerative diseases, including stroke (Hillard, 2008), traumatic brain injury (Schurman and Lichtman, 2017), Alzheimer’s disease (Bisogno and Di Marzo, 2008), Huntington’s disease (Maccarrone et al., 2007), Parkinson’s disease (Di Marzo et al., 2000; Maccarrone et al., 2003), and multiple sclerosis (Baker et al., 2000). </plain></SENT>
<SENT sid="37" pm="."><plain>It is hypothesized that regulation of ECS activity may provide therapeutic benefit for these types of neurological diseases (Scotter et al., 2010). </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>Niemann-Pick type C (NPC) is a neurodegenerative lysosomal storage disorder, which is associated with mutations in either of the genes encoding Niemann-Pick C1 protein (NPC1) or NPC2 (Vanier and Millat, 2003). </plain></SENT>
<SENT sid="39" pm="."><plain>Both genes encode lysosomal proteins that are sequentially involved in cholesterol transport out of the lysosomes via a so far unknown mechanism. </plain></SENT>
<SENT sid="40" pm="."><plain>Defects in the function of the soluble NPC2 or the lysosomal membrane protein NPC1 leads to primary accumulation of cholesterol and secondary storage of sphingomyelin, sphingosine, and glycosphingolipids in lysosomes of multiple cell types, thereby leading to visceral complications such as enlarged liver and spleen combined with progressive neurological disease (Vanier and Millat, 2003). </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>A NPC mouse model is available. </plain></SENT>
<SENT sid="42" pm="."><plain>These NPC mice have previously been studied using ABPP with a retaining β-glucosidase probe (Marques et al., 2015). </plain></SENT>
<SENT sid="43" pm="."><plain>This study showed increased activity of the non-lysosomal glucosylceramidase (GBA2) in NPC1 knockout mice (and consistent increased abundance of the protein by Western blot). </plain></SENT>
<SENT sid="44" pm="."><plain>Importantly, pharmacological inhibition of GBA2 ameliorated the neuropathology of these mice (Marques et al., 2015). </plain></SENT>
<SENT sid="45" pm="."><plain>Miglustat is approved as a drug, and initially thought to work through substrate reduction by inhibiting glucosylceramide synthase (Nietupski et al., 2012). </plain></SENT>
<SENT sid="46" pm="."><plain>However, as we have shown before, the molecular mechanism does not involve glucosylceramide synthase, and we hypothesized that the therapeutic effect seems at least partly due to off-target inhibition of Miglustat on GBA2 (Marques et al., 2015). </plain></SENT>
<SENT sid="47" pm="."><plain>It has been suggested that accumulation of sterols in lysosomes impaired in NPC1 (or NPC2) causes a more general lysosome dysfunction involving multiple hydrolases, such as lysosomal glucocerebrosidase (GBA; Ferraz et al., 2016). </plain></SENT>
<SENT sid="48" pm="."><plain>Additionally, mutations in NPC1 or NPC2 genes result in severe progressive neurodegeneration. </plain></SENT>
<SENT sid="49" pm="."><plain>These observations led us to hypothesize that the hydrolases of the ECS might play a role in this disease. </plain></SENT>
<SENT sid="50" pm="."><plain>There is no treatment available for NPC patients. </plain></SENT>
<SENT sid="51" pm="."><plain>Additionally, there is no information available about the status of the ECS in Niemann-Pick. </plain></SENT>
<SENT sid="52" pm="."><plain>Therefore, we set out to measure endocannabinoid hydrolase activity in the NPC mouse model using ABPP. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="s1"><title><text><SENT sid="53" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec><title><text><SENT sid="54" pm="."><plain>Animals </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>Npc1-/- mice, along with wild-type littermates (Npc1+/+), were generated as published previously (Marques et al., 2015). </plain></SENT>
<SENT sid="56" pm="."><plain>Briefly, the heterozygous BALB/c Nctr-Npc1m1N/J mice (stock number 003092) were obtained from The Jackson Laboratory (Bar Harbor, ME, United States). </plain></SENT>
<SENT sid="57" pm="."><plain>The mice used in the current study were crossed for six generations in c57/bl6 background. </plain></SENT>
<SENT sid="58" pm="."><plain>Mouse pups were genotyped according to published protocols (Loftus et al., 1997). </plain></SENT>
<SENT sid="59" pm="."><plain>The mice were housed at the Institute Animal Core Facility in a temperature- and humidity-controlled room with a 12-h light/dark cycle and given free access to food and water ad libitum. </plain></SENT>
<SENT sid="60" pm="."><plain>All animal protocols were approved by the Institutional Animal Welfare Committee of the Academic Medical Centre Amsterdam in Netherlands. </plain></SENT>
<SENT sid="61" pm="."><plain>At the age of 69 days, animals were first anesthetized with a dose of Hypnorm (0.315 mg/mL fenyl citrate and 10 mg/mL fluanisone) and Dormicum (5 mg/mL midazolam) according to their weight. </plain></SENT>
<SENT sid="62" pm="."><plain>The given dose was 80 μL/10 g body weight. </plain></SENT>
<SENT sid="63" pm="."><plain>Blood was collected by a heart puncture followed by cervical dislocation. </plain></SENT>
<SENT sid="64" pm="."><plain>Brains were dissected, rinsed with phosphate-buffered saline (PBS), snap frozen in liquid N2, and stored at -80°C for biochemistry. </plain></SENT>
<SENT sid="65" pm="."><plain>Brain tissue was obtained from six female mice, three wildtype and three knockout. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="66" pm="."><plain>Preparation of Mouse Tissue Proteome </plain></SENT>
</text></title><p><text><SENT sid="67" pm="."><plain>The mouse brains were cut in half with a scalpel through the midsection (sagittal plane). </plain></SENT>
<SENT sid="68" pm="."><plain>The mouse brain halves were slowly thawed on ice. </plain></SENT>
<SENT sid="69" pm="."><plain>The thawed mouse brain halves were dounce homogenized in 1.5-mL cold (4°C) lysis buffer (20 mM HEPES pH 7.2, 2 mM DTT, 1 mM MgCl2, 25 U/mL benzonase) and incubated for 15 min on ice. </plain></SENT>
<SENT sid="70" pm="."><plain>The suspension was centrifuged (2500 g, 3 min, 4°C) to remove debris. </plain></SENT>
<SENT sid="71" pm="."><plain>The supernatant was collected and transferred to an ultracentrifuge tube. </plain></SENT>
<SENT sid="72" pm="."><plain>The debris was resuspended in 0.25-mL lysis buffer and resubjected to centrifugation. </plain></SENT>
<SENT sid="73" pm="."><plain>The combined supernatants were collected and subjected to ultracentrifugation (100,000 g, 45 min, 4°C, Beckman Coulter, Type Ti70 rotor). </plain></SENT>
<SENT sid="74" pm="."><plain>This yielded the membrane fraction as a pellet and the cytosolic fraction in the supernatant. </plain></SENT>
<SENT sid="75" pm="."><plain>The supernatant was collected and the membrane fraction was suspended in 1.5-mL storage buffer (20 mM HEPES pH 7.2, 2 mM DTT). </plain></SENT>
<SENT sid="76" pm="."><plain>The total protein concentration was determined with Quick Start Bradford assay (Bio-Rad). </plain></SENT>
<SENT sid="77" pm="."><plain>Membranes and supernatant fractions were both diluted to either 1.0 or 2.0 mg/mL (for proteomics and gel-based ABPP, respectively) and were used directly or flash frozen in liquid nitrogen and stored in aliquots at -80°C until use. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="78" pm="."><plain>Activity-Based Protein Profiling </plain></SENT>
</text></title><sec><title><text><SENT sid="79" pm="."><plain>Gel-Based </plain></SENT>
</text></title><p><text><SENT sid="80" pm="."><plain>Mouse brain cytosol or membrane fraction (2.0 mg/mL) was incubated with activity-based probe MB064 (250 nM), TAMRA-FP (500 nM), or DH379 (1 μM) (20 min, rt, 2.5% DMSO). </plain></SENT>
<SENT sid="81" pm="."><plain>For the competition experiments with inhibitor DH376, this step was preceded by incubation with 100 nM inhibitor (30 min, rt, 2.5% DMSO). </plain></SENT>
<SENT sid="82" pm="."><plain>For the competition experiments with probe MB108, this step was preceded by incubation with 10 μM probe (30 min, 37°C, 2.5% DMSO). </plain></SENT>
<SENT sid="83" pm="."><plain>Laemmli buffer was added to quench the protein activity and the mixture was allowed to stand at rt for at least 5 min before the samples were loaded and resolved on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel (10% acrylamide), together with PageRuler Plus Prestained Protein Ladder (Thermo Scientific). </plain></SENT>
<SENT sid="84" pm="."><plain>The gels were scanned using a ChemiDoc (Bio-Rad, Cy3 channel: expose 180 s for MB064, 60 s for DH379/TAMRA-FP, Cy5 channel 10 s for marker). </plain></SENT>
<SENT sid="85" pm="."><plain>After fluorescent scanning, the gels were stained with a Coomassie staining solution [0.25% (w/v) Coomassie Brilliant Blue in 50% MeOH, 10% AcOH, 40% MilliQ (v/v/v)]. </plain></SENT>
<SENT sid="86" pm="."><plain>The gels were scanned after destaining with MilliQ. </plain></SENT>
<SENT sid="87" pm="."><plain>Both the fluorescence and Coomassie images were analyzed using Image Lab 5.2. </plain></SENT>
<SENT sid="88" pm="."><plain>The Coomassie gel is used to determine protein loading (automatic lane/band detection, background subtraction not enabled, select whole lane as band). </plain></SENT>
<SENT sid="89" pm="."><plain>The fluorescence bands are quantified using automatic lane/band detection with background subtraction enabled. </plain></SENT>
<SENT sid="90" pm="."><plain>Using the Coomassie-corrected gel fluorescence values, the average is calculated for WT and KO and a two-sided Student’s t-test is performed. </plain></SENT>
<SENT sid="91" pm="."><plain>The activities of proteins were relatively quantified by setting the average WT at 100%. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="92" pm="."><plain>Western Blot </plain></SENT>
</text></title><p><text><SENT sid="93" pm="."><plain>After the SDS-PAGE gel was resolved and imaged, proteins were transferred to 0.2-μm polyvinylidene difluoride membranes with a Trans-Blot TurboTM Transfer system (Bio-Rad). </plain></SENT>
<SENT sid="94" pm="."><plain>Membranes were washed with TBS (50 mM Tris, 150 mM NaCl) and blocked with 5% milk (w/v, Elk magere melkpoeder, FrieslandCampina) in TBST (50 mM Tris, 150 mM NaCl, 0.05% Tween 20) for 1 h at rt. </plain></SENT>
<SENT sid="95" pm="."><plain>Membranes were then incubated with the primary antibody anti-DAGLα (1:1000, Cell Signaling Technology, #13626) in 5% BSA (w/v) in TBST (o/n, 4°C), washed with TBST, incubated with matching secondary antibody HRP-coupled-goat-anti-rabbit (1:5000, Santa Cruz, sc2030) in 5% milk in TBST (1 h, rt) and washed with TBST and TBS. </plain></SENT>
<SENT sid="96" pm="."><plain>Imaging solution (10 mL Luminol, 100 μL ECL enhancer, 3 μL H2O2) was added to develop membranes and chemiluminescence was detected on the ChemiDoc (Bio-Rad) using standard chemiluminescence settings. </plain></SENT>
<SENT sid="97" pm="."><plain>The signal was normalized to Coomassie staining and quantified with Image Lab 5.2. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="98" pm="."><plain>Proteomics </plain></SENT>
</text></title><p><text><SENT sid="99" pm="."><plain>Mouse brain membrane or soluble proteome (245 μL, 1.0 mg/mL) was incubated with 5 μL 0.5 mM MB108 (10 μM) or FP-Biotin (10 μM) for 1 h at rt. </plain></SENT>
<SENT sid="100" pm="."><plain>The labeling reaction was quenched and excess probe was removed by chloroform/methanol precipitation: 250 μL MilliQ, 666 μL MeOH, 166 μL CHCl3, and 150 μL MilliQ added subsequently to each sample with a brief vortex after each addition. </plain></SENT>
<SENT sid="101" pm="."><plain>After centrifugation (4000 rpm, 10 min), the top and bottom layer surrounding the floating protein pellet was removed. </plain></SENT>
<SENT sid="102" pm="."><plain>600 μL MeOH was added and the pellet was resuspended by sonication with a probe sonicator (10 s, 30% amplitude). </plain></SENT>
<SENT sid="103" pm="."><plain>After centrifugation (14,000 rpm, 5 min), the methanol was removed and the protein pellet was redissolved in 250 μL 6 M urea/25 mM ammonium bicarbonate and allowed to incubate for 15 min. </plain></SENT>
<SENT sid="104" pm="."><plain>2.5 μL 1 M DTT was added and the mixture was heated to 65°C for 15 min. </plain></SENT>
<SENT sid="105" pm="."><plain>The sample was allowed to cool to rt (∼5 min) before 20 μL 0.5 M iodoacetamide was added and the sample was alkylated for 30 min in the dark. </plain></SENT>
<SENT sid="106" pm="."><plain>70 μL 10% (wt/vol) SDS was added and the proteome was heated for 5 min at 65°C. </plain></SENT>
<SENT sid="107" pm="."><plain>The sample was diluted with 2 mL PBS. </plain></SENT>
<SENT sid="108" pm="."><plain>50 μL of 50% slurry of Avidin-Agarose from egg white (Sigma-Aldrich) was washed with PBS and added to the proteome sample in 1 mL PBS. </plain></SENT>
<SENT sid="109" pm="."><plain>The beads were incubated with the proteome for 3 h, while rotating. </plain></SENT>
<SENT sid="110" pm="."><plain>The beads were isolated by centrifugation (2500 g, 2 min) and washed with 0.5% (wt/vol) SDS in PBS (1×) and PBS (3×). </plain></SENT>
<SENT sid="111" pm="."><plain>The proteins were digested overnight with 500 ng sequencing grade trypsin (Promega) in 250 μL on-bead digestion buffer (100 mM Tris pH 8, 100 mM NaCl, 1 mM CaCl2, 2% ACN) at 37°C with vigorous shaking. </plain></SENT>
<SENT sid="112" pm="."><plain>The pH was adjusted with formic acid to pH 3 and the beads were removed. </plain></SENT>
<SENT sid="113" pm="."><plain>The peptides were isotopically labeled by on-stage tip dimethyl labeling. </plain></SENT>
<SENT sid="114" pm="."><plain>Wild-type and knockout samples were differently labeled with isotopic dimethyl labeling and combined after labeling to allow comparison (wild-type light and knockout heavy). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="115" pm="."><plain>On-Stage Tip Dimethyl Labeling </plain></SENT>
</text></title><p><text><SENT sid="116" pm="."><plain>The stage tips were made by inserting C18 material in a 200-μL pipet tip. </plain></SENT>
<SENT sid="117" pm="."><plain>The step-wise procedure given in the Table 1 was followed for stage tip desalting and dimethyl labeling. </plain></SENT>
<SENT sid="118" pm="."><plain>The solutions were eluted by centrifugal force and the constitutions of the reagents are given below. </plain></SENT>
<SENT sid="119" pm="."><plain>For label-free quantification samples, steps 6 and 7 are omitted. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><text><SENT sid="120" pm="."><plain>Step-wise on-stage tip dimethyl labeling procedure. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>Step </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>Aim </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>Solution </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>Centrifugation </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>1 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>Conditioning </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>Methanol (50 μL) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>2 min 600 g </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>2 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>Conditioning </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>Stage tip solution B (50 μL) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>2 min 600 g </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>Conditioning </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>Stage tip solution A (50 μL) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>2 min 600 g </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>4 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>Loading </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>Load samples on stage tips </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>2.5 min 800 g </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>5 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>Washing </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>Stage tip solution A (100 μL) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>2.5 min 800 g </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>6 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>Dimethyl labeling (5×) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>20/20/40/40/30 μL L or M reagent </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>5 min 400 g </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>7 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>Washing </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>Stage tip solution A (100 μL) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>2.5 min 800 g </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>8 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>Elution </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>Stage tip solution B (100 μL) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>2.5 min 800 g </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="157" pm="."><plain>Stage tip solution A is 0.5% (vol/vol) FA in H2O. </plain></SENT>
<SENT sid="158" pm="."><plain>Stage tip solution B is 0.5% (vol/vol) FA in 80% (vol/vol) ACN in H2O. </plain></SENT>
<SENT sid="159" pm="."><plain>Dimethyl labeling reagents: phosphate buffer (50 mM; pH 7.5) with NaBH3CN 0.03 M containing either 2% (vol/vol) CH2O (Light) or CD2O (Medium). </plain></SENT>
<SENT sid="160" pm="."><plain>After the final elution step, the desired heavy and light samples were combined and concentrated on a Speedvac to remove the ACN. </plain></SENT>
<SENT sid="161" pm="."><plain>The residue was reconstituted in 95/3/0.1 H2O/ACN/FA (vol/vol) before LC/MS analysis. </plain></SENT>
<SENT sid="162" pm="."><plain>Tryptic peptides were measured either on an Orbitrap or Synapt mass spectrometer. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="163" pm="."><plain>Orbitrap </plain></SENT>
</text></title><p><text><SENT sid="164" pm="."><plain>Tryptic peptides were analyzed on a Surveyor nanoLC system (Thermo) hyphenated to a LTQ-Orbitrap mass spectrometer (Thermo) as previously described. </plain></SENT>
<SENT sid="165" pm="."><plain>Briefly, emitter, trap and analytical column (C18, 120Å) were purchased from Nanoseparations (Nieuwkoop, Netherlands) and mobile phases (A: 0.1% formic acid/H2O, B: 0.1% formic acid/ACN) were made with ULC/MS grade solvents (Biosolve). </plain></SENT>
<SENT sid="166" pm="."><plain>General mass spectrometric conditions were: electrospray voltage of 1.8–2.5 kV, no sheath and auxiliary gas flow, capillary voltage 40 V, tube lens voltage 155 V, and ion transfer tube temperature 150°C. </plain></SENT>
<SENT sid="167" pm="."><plain>Polydimethylcyclosiloxane (m/z = 445.12002) and dioctyl phthalate ions (m/z = 391.28429) from the environment were used as lock mass. </plain></SENT>
<SENT sid="168" pm="."><plain>Some 10 μL of the samples was pressure loaded on the trap column for 5 min with a 10-μL/min flow and separated with a gradient of 35 min 5–30% B, 15 min 30–60% B, and 5 min A at a flow of 300 μL/min split to 250 nL/min by the LTQ divert valve. </plain></SENT>
<SENT sid="169" pm="."><plain>Full MS scans (300–2000 m/z) acquired at high mass resolution (60,000 at 400 m/z, maximum injection time 1000 ms, AGC 106) in the Orbitrap was followed by three MS/MS fragmentations in the LTQ linear ion trap (AGC 5 × 103, max inj time 120 ms) from the three most abundant ions. </plain></SENT>
<SENT sid="170" pm="."><plain>MS/MS settings were: collision gas pressure 1.3 mT, normalized collision energy 35%, ion selection threshold of 750 counts, activation q = 0.25, and activation time 30 ms. </plain></SENT>
<SENT sid="171" pm="."><plain>Ions of z &lt; 2 or unassigned were not analyzed and fragmented precursor ions were measured twice within 10 s and were dynamically excluded for 60 s. </plain></SENT>
<SENT sid="172" pm="."><plain>Data analysis was performed using Maxquant with acetylation (protein N term) and oxidation (M) as variable modifications. </plain></SENT>
<SENT sid="173" pm="."><plain>The false discovery rate was set at 1%, and the peptides were screened against reviewed mouse proteome (Uniprot). </plain></SENT>
<SENT sid="174" pm="."><plain>Serine hydrolases that were identified in at least two repetitive experiments and for which at least one unique peptide and two peptides in total were identified were considered as valid quantifiable hits. </plain></SENT>
<SENT sid="175" pm="."><plain>For proteins identified by both probes, the normalized ratios from Maxquant were combined for further analysis. </plain></SENT>
<SENT sid="176" pm="."><plain>The binary logarithm of each ratio was compared to 0 with a Student’s t-test. </plain></SENT>
<SENT sid="177" pm="."><plain>The resulting p values were subjected to a Benjamini–Hochberg correction, setting the false discovery rate at 10% (q = 0.1). </plain></SENT>
<SENT sid="178" pm="."><plain>Briefly, the p values of all quantifiable hits were ordered from lowest to highest, and the Benjamini–Hochberg statistic was calculated as q × (position in the list) divided by the number of tests. </plain></SENT>
<SENT sid="179" pm="."><plain>Subsequently, the proteins for which the p value is smaller than the BH statistic are controlled for a FDR of q × 10%. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="180" pm="."><plain>Synapt </plain></SENT>
</text></title><p><text><SENT sid="181" pm="."><plain>The peptides were measured as described previously for the NanoACQUITY UPLC System coupled to SYNAPT G2-Si high definition mass spectrometer. </plain></SENT>
<SENT sid="182" pm="."><plain>A trap-elute protocol, where 1 μL of the digest is loaded on a trap column (C18 100Å, 5 μM, 180 μM × 20 mm, Waters) followed by elution and separation on the analytical column (HSS-T3 C18 1.8 μM, 75 μM × 250 mm, Waters). </plain></SENT>
<SENT sid="183" pm="."><plain>The sample is brought onto this column at a flow rate of 10 μL/min with 99.5% solvent A for 2 min before switching to the analytical column. </plain></SENT>
<SENT sid="184" pm="."><plain>Peptide separation is achieved using a multistep concave gradient based on the gradients used in Distler et al. (2016). </plain></SENT>
<SENT sid="185" pm="."><plain>The column is re-equilibrated to initial conditions after washing with 90% solvent B. </plain></SENT>
<SENT sid="186" pm="."><plain>The rear seals of the pump are flushed every 30 min with 10% (vol/vol) ACN. </plain></SENT>
<SENT sid="187" pm="."><plain>[Glu1]-fibrinopeptide B (GluFib) is used as a lock mass compound. </plain></SENT>
<SENT sid="188" pm="."><plain>The auxiliary pump of the LC system is used to deliver this peptide to the reference sprayer (0.2 μL/min). </plain></SENT>
<SENT sid="189" pm="."><plain>A UDMSe method is set up as described in Distler et al. (2016). </plain></SENT>
<SENT sid="190" pm="."><plain>Briefly, the mass range is set from 50 to 2,000 Da with a scan time of 0.6 s in positive, resolution mode. </plain></SENT>
<SENT sid="191" pm="."><plain>The collision energy is set to 4 V in the trap cell for low energy MS mode. </plain></SENT>
<SENT sid="192" pm="."><plain>For the elevated energy scan, the transfer cell collision energy is ramped using drift time specific collision energies (Distler et al., 2014). </plain></SENT>
<SENT sid="193" pm="."><plain>The lock mass is sampled every 30 s. </plain></SENT>
<SENT sid="194" pm="."><plain>Raw data are processed in PLGS (v3.0.3) and ISOQuant v1.5. </plain></SENT>
</text></p></sec></sec></sec></SecTag><SecTag type="RESULTS"><sec><title><text><SENT sid="195" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="196" pm="."><plain>In 95% of the patients afflicted by NPC, mutations in NPC1 are observed. </plain></SENT>
<SENT sid="197" pm="."><plain>Therefore, the role of the ECS in this disease was investigated by comparison of endocannabinoid hydrolase activity between Npc1+/+ and Npc1-/- mouse brains. </plain></SENT>
<SENT sid="198" pm="."><plain>First, labeling profiles of MB064, DH379, and FP-TAMRA in wild-type and knockout mouse brains was evaluated (Figure 2A). </plain></SENT>
<SENT sid="199" pm="."><plain>Membrane and soluble fractions of both wild-type and knockout tissue were labeled with each probe separately, resolved on SDS-PAGE and visualized using in gel fluorescence scanning. </plain></SENT>
<SENT sid="200" pm="."><plain>Coomassie staining was used as a protein loading control. </plain></SENT>
<SENT sid="201" pm="."><plain>The fluorescence intensity of the bands corresponding to DAGLα (∼120 kDa), ABHD12 (∼50 kDa), ABHD6 (∼35 kDa), and FAAH (∼60 kDa) were quantified to determine the relative enzyme activity between knockout and wildtype (Figure 2B). </plain></SENT>
<SENT sid="202" pm="."><plain>Using the FP-TAMRA probe, the two bands corresponding to MAGL (∼35 kDa) were observed, but due to band overlap with ABHD6 these cannot be accurately quantified. </plain></SENT>
<SENT sid="203" pm="."><plain>Labeling of DAGLα significantly decreased in the knockout mice as compared to wildtype, while ABHD6 and ABHD12 activity was the same. </plain></SENT>
<SENT sid="204" pm="."><plain>FAAH labeling was slightly decreased in the knockout, but this decrease was not statistically significant. </plain></SENT>
<SENT sid="205" pm="."><plain>In the cytosolic fraction, an increase in intensity of a 75-kDa band as labeled by MB064 and FP-TAMRA was observed in the knockout brains. </plain></SENT>
<SENT sid="206" pm="."><plain>As reported previously (Gao et al., 2010; Baggelaar et al., 2017), DAGLα is identified as two separate bands. </plain></SENT>
<SENT sid="207" pm="."><plain>Remarkably, only the fluorescent band corresponding to the higher molecular weight was significantly decreased in the Npc1-/- mice as quantified by two separate probes MB064 and DH379 (Figure 2C). </plain></SENT>
<SENT sid="208" pm="."><plain>Both bands can be labeled with a DAGLα antibody and are absent in DAGLα KO mice (Figure 2D). </plain></SENT>
<SENT sid="209" pm="."><plain>To see if this observation was due to a decrease of protein abundance, a Western blot against DAGLα was performed (Figure 2E). </plain></SENT>
<SENT sid="210" pm="."><plain>The signal of antibody labeling was quantified (Figure 2F). </plain></SENT>
<SENT sid="211" pm="."><plain>The same pattern was observed for relative abundance as for relative activity: only the upper band corresponding to DAGLα is significantly decreased (Figures 2C,F). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" position="float"><label>FIGURE 2</label><caption><p><text><SENT sid="212" pm="."><plain>Gel-based Npc1+/+ (WT) vs. Npc1-/- (KO) comparison. (A) Enzyme activity in the brain fractions as measured by the probes MB064, DH379, and FP-TAMRA. (B) Quantification of relative enzyme activity in WT and KO for probe targets (average WT is set to 100%). n = 3 (mice), n = 2 (MB064), or n = 1 (DH379 and FP-TAMRA). (C) Quantification of probe labeling of the two observed bands for DAGLα as measured by MB064 and DH379 [gels: (A)]. </plain></SENT>
<SENT sid="213" pm="."><plain>Three mice per condition (N = 3) and three probe labeling experiments per lysate (n = 3). (D) DAGLα activity and abundance in DAGLα WT and KO mouse brain membrane proteome as measured by the probe MB064 and an anti-DAGLα antibody. (E) DAGLα abundance in NPC1 WT and KO mouse brain membrane proteome. (F) Quantification of antibody labeling of the two observed bands for DAGLα as measured by anti-DAGLα [blot: (E)]. </plain></SENT>
<SENT sid="214" pm="."><plain>Mean ± standard deviation is shown. ∗p &lt; 0.05 (Student’s t-test). </plain></SENT>
</text></p></caption><graphic xlink:href="fnins-12-00440-g002"/></fig></SecTag><p><text><SENT sid="215" pm="."><plain>Although several endocannabinoid enzymes can be quantified with gel-based ABPP, multiple bands remain unidentified (Figure 2A). </plain></SENT>
<SENT sid="216" pm="."><plain>Additional enzymes can be identified using a sensitive mass spectrometry-based method for ABPP (chemical proteomics). </plain></SENT>
<SENT sid="217" pm="."><plain>Therefore, to study a broader range of serine hydrolases and to confirm our observations from the gel-based assay, we also employed a chemical proteomics method using FP biotin and MB108 to assess the role of the ECS in NPC1. </plain></SENT>
<SENT sid="218" pm="."><plain>The enzymatic activity of 41 hydrolases in NPC1 knockout mouse brain were identified and compared with wild-type mouse brains (Figure 3). </plain></SENT>
<SENT sid="219" pm="."><plain>In line with the gel-based ABPP, we did not find any significant difference in the endocannabinoid hydrolase activity (ABHD12, ABHD6, FAAH, and MAGL) in NPC1 wild-type vs. knockout mice brain proteomes. </plain></SENT>
<SENT sid="220" pm="."><plain>The activity of endocannabinoid hydrolase ABHD4 is also unaltered in knockout compared to wildtype. </plain></SENT>
<SENT sid="221" pm="."><plain>Remarkably, and in contrast to the gel-based ABPP results, DAGLα activity in knockout mice brain proteomes was not decreased compared to wild-type mice. </plain></SENT>
<SENT sid="222" pm="."><plain>Of note, in a control experiment, biotinylated probe MB108 competes with both DAGLα bands labeled by the fluorescent probe MB064. </plain></SENT>
<SENT sid="223" pm="."><plain>Additionally, DAGL inhibitor DH376 did reduce DAGLα labeling in the chemical proteomics assay (Supplementary Figure S2). </plain></SENT>
<SENT sid="224" pm="."><plain>Finally, three hydrolases were significantly increased in knockout mouse brains compared to wild-type brains: retinoid-inducible serine carboxypeptidase (SCPEP1), cathepsin A (CTSA), and palmitoyl-protein thioesterase 1 (PPT1) (Figure 3). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F3" position="float"><label>FIGURE 3</label><caption><p><text><SENT sid="225" pm="."><plain>Chemical proteomics comparison of Npc1+/+ (WT) vs. Npc1-/- (KO). </plain></SENT>
<SENT sid="226" pm="."><plain>Log2 ratio of enzyme activity in Npc1-/- brain proteome compared to Npc1+/+. </plain></SENT>
<SENT sid="227" pm="."><plain>Activity was measured using FP-biotin or MB108 (both 10 μM). </plain></SENT>
<SENT sid="228" pm="."><plain>The data from both probes were combined for both the cytosolic and membrane fraction. </plain></SENT>
<SENT sid="229" pm="."><plain>The mean and standard deviation are shown. </plain></SENT>
<SENT sid="230" pm="."><plain>Endocannabinoid related enzymes are underlined. </plain></SENT>
<SENT sid="231" pm="."><plain>Statistical analysis by means of Student’s t-test (each ratio was compared to a log2 ratio of 0) and the resulting p values were subjected to Benjamini–Hochberg correction, setting the false discovery rate at 10% (∗ indicates significant difference). </plain></SENT>
</text></p></caption><graphic xlink:href="fnins-12-00440-g003"/></fig></SecTag></sec></SecTag><SecTag type="DISCUSS"><sec><title><text><SENT sid="232" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="233" pm="."><plain>We used ABPP to quantify the activity of the endocannabinoid hydrolases FAAH, ABHD6, ABHD12, ABHD4, and MAGL in NPC1 knockout mice and found that their activity is not affected in wild-type vs. NPC1 knockout mice. </plain></SENT>
<SENT sid="234" pm="."><plain>DAGLα activity seems to be decreased in the knockout mice based on the gel-based ABPP results. </plain></SENT>
<SENT sid="235" pm="."><plain>However, we found a discrepancy in the gel-based ABPP assay and the chemical proteomics assay in DAGLα activity between the NPC1 knockout mouse brains compared to wild-type mice. </plain></SENT>
<SENT sid="236" pm="."><plain>This discrepancy can possibly be caused by technical factors inherent to the two applied methodologies. </plain></SENT>
<SENT sid="237" pm="."><plain>In the gel-based ABPP assay, only the labeling of the upper DAGLα-band was abolished in the NPC1 knockout brain proteome. </plain></SENT>
<SENT sid="238" pm="."><plain>It could be that the peptides from the protein corresponding to the upper band from the wild-type mouse proteome are not detected in the mass spectrometer due to post-translational modifications, such as phosphorylation, acetylation, methylation, palmitoylation, or glycosylation. </plain></SENT>
<SENT sid="239" pm="."><plain>Peptides with such modifications are not found in our assay. </plain></SENT>
<SENT sid="240" pm="."><plain>If this would be true, a decrease in DAGLα activity in the NPC1 knockout mice would not be detected. </plain></SENT>
<SENT sid="241" pm="."><plain>Further experiments, such as direct quantification of 2-AG levels, are required to confirm a decrease in DAGLα activity in Niemann-Pick mice. </plain></SENT>
<SENT sid="242" pm="."><plain>In addition, it would be interesting to find the origin and role of the altered modification of DAGLα in NPC. </plain></SENT>
<SENT sid="243" pm="."><plain>If the gel-based ABPP results are confirmed, it would be worthwhile to measure 2-AG levels and test the hypothesis that decreased DAGL activity might represent a neuroprotective response by lowering the formation of pro-inflammatory prostaglandins (Ogasawara et al., 2016). </plain></SENT>
<SENT sid="244" pm="."><plain>Alternatively, it is known that 2-AG reduces cytotoxic edema in traumatic brain injury (Panikashvili et al., 2001), therefore boosting 2-AG brain levels by inhibition of MAGL may constitute a neuroprotective response. </plain></SENT>
</text></p><p><text><SENT sid="245" pm="."><plain>Finally, we found that the activities of three non-endocannabinoid hydrolases, namely, CTSA, PPT1, and SCPEP1, were significantly elevated in NPC1 knockout mouse brains. </plain></SENT>
<SENT sid="246" pm="."><plain>These enzymes are lysosomal proteins, which is in line with the important role of NPC1 in lysosomes. </plain></SENT>
<SENT sid="247" pm="."><plain>SCPEP1 shows homology with CTSA (Kollmann et al., 2009) and a study with double knockout of SCPEP1 and CTSA suggests they share the same peptide substrate (Pan et al., 2014). </plain></SENT>
<SENT sid="248" pm="."><plain>Single knockout of SCPEP1 in mice resulted in viable mice without lysosomal impairment (Kollmann et al., 2009). </plain></SENT>
<SENT sid="249" pm="."><plain>Mutations in the CTSA gene cause galactosialidosis in humans (Galjart et al., 1990) and secondary deficiencies of beta-galactosidase and neuraminidase. </plain></SENT>
<SENT sid="250" pm="."><plain>This same phenotype is mirrored in a CTSA knockout mice mouse model (Korah et al., 2003). </plain></SENT>
<SENT sid="251" pm="."><plain>The protective role of the enzyme for galactosidase and neuraminidase is a structural function of the enzyme: mice with catalytic serine-to-alanine mutation have normal levels of β-galactosidase and neuraminidase (Seyrantepe et al., 2008). </plain></SENT>
<SENT sid="252" pm="."><plain>CTSA inhibitors have been tested in humans (Tillner et al., 2016), and CTSA is a therapeutic target for the treatment of cardiovascular diseases (Schreuder et al., 2014; Petrera et al., 2016). </plain></SENT>
<SENT sid="253" pm="."><plain>Thus, it would be interesting to test CTSA inhibitors in Niemann-Pick models. </plain></SENT>
<SENT sid="254" pm="."><plain>PPT1 is also a lysosomal enzyme (Lu et al., 2002) and the dysregulation of this enzyme causes a lysosomal storage and neurodegenerative disorder; infantile neuronal ceroid lipofuscinosis (Tillner et al., 2016). </plain></SENT>
<SENT sid="255" pm="."><plain>This enzyme removes palmitoyl modifications from proteins that are being degraded in the lysosome. </plain></SENT>
<SENT sid="256" pm="."><plain>In PPT1 knockout mice, cholesterol catabolism is altered (Ahtiainen et al., 2007). </plain></SENT>
<SENT sid="257" pm="."><plain>PPT1 has been proposed to hydrolyze 2-AG and might therefore be involved in the ECS (Wang et al., 2013). In vivo active inhibitors for PPT1 (Cognetta et al., 2015) have been identified and could therefore also be tested in Niemann-Pick models. </plain></SENT>
<SENT sid="258" pm="."><plain>To conclude, we have found no altered activity of endocannabinoid hydrolases in a NPC mouse model using our chemical proteomics assay. </plain></SENT>
<SENT sid="259" pm="."><plain>Three hydrolases were identified with upregulated activity in NPC1 knockout mice, which might be interesting therapeutic target for future studies. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="260" pm="."><plain>Data Availability Statement </plain></SENT>
</text></title><p><text><SENT sid="261" pm="."><plain>The mass spectrometry proteomics datasets generated for this study have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaíno et al., 2016) partner repository with the dataset identifier PXD008979. </plain></SENT>
</text></p></sec><SecTag type="AUTH_CONT"><sec><title><text><SENT sid="262" pm="."><plain>Author Contributions </plain></SENT>
</text></title><p><text><SENT sid="263" pm="."><plain>EvR and AvE carried out the experiments and analyzed gel-based results. </plain></SENT>
<SENT sid="264" pm="."><plain>EvR analyzed the mass spectrometry data and supervised by MB. </plain></SENT>
<SENT sid="265" pm="."><plain>HD synthesized DH379 and supervised sample preparation. </plain></SENT>
<SENT sid="266" pm="."><plain>BF assisted with LC/MS measurements. </plain></SENT>
<SENT sid="267" pm="."><plain>AM and RO performed mice experiments and harvested tissue. </plain></SENT>
<SENT sid="268" pm="."><plain>EvR and MvdS wrote the manuscript, supported by RB and HO. </plain></SENT>
<SENT sid="269" pm="."><plain>MvdS and JA conceived the presented study. </plain></SENT>
<SENT sid="270" pm="."><plain>All authors provided critical feedback. </plain></SENT>
</text></p></sec></SecTag><SecTag type="COMP_INT"><sec><title><text><SENT sid="271" pm="."><plain>Conflict of Interest Statement </plain></SENT>
</text></title><p><text><SENT sid="272" pm="."><plain>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="273" pm="."><plain>We thank ChemAxon for the Instant JChem database management software. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary material"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fnins.2018.00440/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fnins.2018.00440/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Image_1.PDF"><caption><p><text><SENT sid="274" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="B1"><text><SENT sid="275" pm="."><plain>AhtiainenL.KolikovaJ.MutkaA. </plain></SENT>
<SENT sid="276" pm="."><plain>L.LuiroK.GentileM.IkonenE. (2007). Palmitoyl protein thioesterase 1 (Ppt1)-deficient mouse neurons show alterations in cholesterol metabolism and calcium homeostasis prior to synaptic dysfunction. Neurobiol. </plain></SENT>
<SENT sid="277" pm="."><plain>Dis. 28 52–64. 10.1016/j.nbd.2007.06.012 <?supplied-pmid 17656100?>17656100 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="278" pm="."><plain>BaggelaarM. </plain></SENT>
<SENT sid="279" pm="."><plain>P.ChameauP. </plain></SENT>
<SENT sid="280" pm="."><plain>J.KantaeV.HummelJ.HsuK. </plain></SENT>
<SENT sid="281" pm="."><plain>L.JanssenF. (2015). A highly selective, reversible inhibitor identified by comparative chemoproteomics modulates diacylglycerol lipase activity in neurons. J. </plain></SENT>
<SENT sid="282" pm="."><plain>Am. </plain></SENT>
<SENT sid="283" pm="."><plain>Chem. </plain></SENT>
<SENT sid="284" pm="."><plain>Soc. 137 8851–8857. 10.1021/jacs.5b04883 <?supplied-pmid 26083464?>26083464 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="285" pm="."><plain>BaggelaarM. </plain></SENT>
<SENT sid="286" pm="."><plain>P.JanssenF. </plain></SENT>
<SENT sid="287" pm="."><plain>J.van EsbroeckA. </plain></SENT>
<SENT sid="288" pm="."><plain>C.den DulkH.AllaràM.HoogendoornS. (2013). Development of an activity-based probe and in silico design reveal highly selective inhibitors for diacylglycerol lipase-α in brain. Angew. </plain></SENT>
<SENT sid="289" pm="."><plain>Chem. </plain></SENT>
<SENT sid="290" pm="."><plain>Int. </plain></SENT>
<SENT sid="291" pm="."><plain>Ed. 52 12081–12085. 10.1002/anie.201306295 <?supplied-pmid 24173880?>24173880 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="292" pm="."><plain>BaggelaarM. </plain></SENT>
<SENT sid="293" pm="."><plain>P.van EsbroeckA. </plain></SENT>
<SENT sid="294" pm="."><plain>C.van RoodenE. </plain></SENT>
<SENT sid="295" pm="."><plain>J.FloreaB. </plain></SENT>
<SENT sid="296" pm="."><plain>I.OverkleeftH. </plain></SENT>
<SENT sid="297" pm="."><plain>S.MarsicanoG. (2017). Chemical proteomics maps brain region specific activity of endocannabinoid hydrolases. ACS Chem. </plain></SENT>
<SENT sid="298" pm="."><plain>Biol. 12 852–861. 10.1021/acschembio.6b01052 <?supplied-pmid 28106377?>28106377 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="299" pm="."><plain>BakerD.PryceG.CroxfordJ. </plain></SENT>
<SENT sid="300" pm="."><plain>L.BrownP.PertweeR. </plain></SENT>
<SENT sid="301" pm="."><plain>G.MakriyannisA. (2000). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15 300–302. 10.1096/fj.00-0399fje <?supplied-pmid 11156943?>11156943 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="302" pm="."><plain>BisognoT.Di MarzoV. (2008). The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses. Curr. </plain></SENT>
<SENT sid="303" pm="."><plain>Pharm. </plain></SENT>
<SENT sid="304" pm="."><plain>Des. 14 2299–3305. 10.2174/13816120878574002718781980 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="305" pm="."><plain>BlankmanJ. </plain></SENT>
<SENT sid="306" pm="."><plain>L.CravattB. </plain></SENT>
<SENT sid="307" pm="."><plain>F. (2013). Chemical probes of endocannabinoid metabolism. Pharmacol. </plain></SENT>
<SENT sid="308" pm="."><plain>Rev. 65 849–871. 10.1124/pr.112.006387 <?supplied-pmid 23512546?>23512546 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="309" pm="."><plain>ChiurchiùV.van der SteltM.CentonzeD.MaccarroneM. (2017). The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. Prog. </plain></SENT>
<SENT sid="310" pm="."><plain>Neurobiol. 160 82–100. 10.1016/j.pneurobio.2017.10.007 <?supplied-pmid 29097192?>29097192 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="311" pm="."><plain>CognettaA. </plain></SENT>
<SENT sid="312" pm="."><plain>B.NiphakisM. </plain></SENT>
<SENT sid="313" pm="."><plain>J.LeeH. </plain></SENT>
<SENT sid="314" pm="."><plain>C.MartiniM. </plain></SENT>
<SENT sid="315" pm="."><plain>L.HulceJ. </plain></SENT>
<SENT sid="316" pm="."><plain>J.CravattB. </plain></SENT>
<SENT sid="317" pm="."><plain>F. (2015). Selective N-hydroxyhydantoin carbamate inhibitors of mammalian serine hydrolases. Chem. </plain></SENT>
<SENT sid="318" pm="."><plain>Biol. 22 928–937. 10.1016/j.chembiol.2015.05.018 <?supplied-pmid 26120000?>26120000 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="319" pm="."><plain>Di MarzoV.BifulcoM.De PetrocellisL. (2004). The endocannabinoid system and its therapeutic exploitation. Nat. </plain></SENT>
<SENT sid="320" pm="."><plain>Rev. </plain></SENT>
<SENT sid="321" pm="."><plain>Drug Discov. 3 771–784. 10.1038/nrd1495 <?supplied-pmid 15340387?>15340387 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="322" pm="."><plain>Di MarzoV.HillM. </plain></SENT>
<SENT sid="323" pm="."><plain>P.BisognoT.CrossmanA. </plain></SENT>
<SENT sid="324" pm="."><plain>R.BrotchieJ. </plain></SENT>
<SENT sid="325" pm="."><plain>M. (2000). Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease. FASEB J. 14 1432–1438.10877836 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="326" pm="."><plain>DistlerU.KuharevJ.NavarroP.LevinY.SchildH.TenzerS. (2014). Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics. Nat. </plain></SENT>
<SENT sid="327" pm="."><plain>Methods 11 167–170. 10.1038/nmeth.2767 <?supplied-pmid 24336358?>24336358 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="328" pm="."><plain>DistlerU.KuharevJ.NavarroP.TenzerS. (2016). Label-free quantification in ion mobility–enhanced data-independent acquisition proteomics. Nat. </plain></SENT>
<SENT sid="329" pm="."><plain>Protoc. 11 795–812. 10.1038/nprot.2016.042 <?supplied-pmid 27010757?>27010757 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="330" pm="."><plain>FerrazM. </plain></SENT>
<SENT sid="331" pm="."><plain>J.MarquesA. </plain></SENT>
<SENT sid="332" pm="."><plain>R.GasparP.MirzaianM.van RoomenC.OttenhoffR. (2016). Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders. Mol. </plain></SENT>
<SENT sid="333" pm="."><plain>Genet. </plain></SENT>
<SENT sid="334" pm="."><plain>Metab. 117 186–193. 10.1016/j.ymgme.2015.12.006 <?supplied-pmid 26750750?>26750750 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="335" pm="."><plain>GaljartN. </plain></SENT>
<SENT sid="336" pm="."><plain>J.GillemansN.MeijerD.D’AzzoA. (1990). Mouse “protective protein”. J. </plain></SENT>
<SENT sid="337" pm="."><plain>Biol. </plain></SENT>
<SENT sid="338" pm="."><plain>Chem. 265 4678–4684.2106523 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="339" pm="."><plain>GaoY.VasilyevD. </plain></SENT>
<SENT sid="340" pm="."><plain>V.GoncalvesM. </plain></SENT>
<SENT sid="341" pm="."><plain>B.HowellF. </plain></SENT>
<SENT sid="342" pm="."><plain>V.HobbsC.ReisenbergM. (2010). Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J. </plain></SENT>
<SENT sid="343" pm="."><plain>Neurosci. 30 2017–2024. 10.1523/JNEUROSCI.5693-09.2010 <?supplied-pmid 20147530?>20147530 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="344" pm="."><plain>HillardC. (2008). Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr. </plain></SENT>
<SENT sid="345" pm="."><plain>Pharm. </plain></SENT>
<SENT sid="346" pm="."><plain>Des. 14 2347–2361. 10.2174/13816120878574005418781985 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="347" pm="."><plain>KollmannK.DammeM.DeuschlF.KahleJ.D’HoogeR.Lüllmann-RauchR. (2009). Molecular characterization and gene disruption of mouse lysosomal putative serine carboxypeptidase 1. FEBS J. 276 1356–1369. 10.1111/j.1742-4658.2009.06877.x <?supplied-pmid 19187242?>19187242 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="348" pm="."><plain>KorahN.SmithC. </plain></SENT>
<SENT sid="349" pm="."><plain>E.D’AzzoA.MuiJ.HermoL. (2003). Characterization of cell- and region-specific abnormalities in the epididymis of cathepsin A deficient mice. Mol. </plain></SENT>
<SENT sid="350" pm="."><plain>Reprod. </plain></SENT>
<SENT sid="351" pm="."><plain>Dev. 66 358–373. 10.1002/mrd.10359 <?supplied-pmid 14579412?>14579412 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="352" pm="."><plain>LiuY.PatricelliM. </plain></SENT>
<SENT sid="353" pm="."><plain>P.CravattB. </plain></SENT>
<SENT sid="354" pm="."><plain>F. (1999). Activity-based protein profiling: the serine hydrolases. PNAS 96 14694–14699. 10.1073/pnas.96.26.1469410611275 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="355" pm="."><plain>LoftusS. </plain></SENT>
<SENT sid="356" pm="."><plain>K.MorrisJ. </plain></SENT>
<SENT sid="357" pm="."><plain>A.CarsteaE. </plain></SENT>
<SENT sid="358" pm="."><plain>D.GuJ. </plain></SENT>
<SENT sid="359" pm="."><plain>Z.CummingsC.BrownA. (1997). Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science 277 232–236. 10.1126/science.277.5323.232 <?supplied-pmid 9211850?>9211850 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="360" pm="."><plain>LuJ. </plain></SENT>
<SENT sid="361" pm="."><plain>Y.VerkruyseL. </plain></SENT>
<SENT sid="362" pm="."><plain>A.HofmannS. </plain></SENT>
<SENT sid="363" pm="."><plain>L. (2002). The effects of lysosomotropic agents on normal and INCL cells provide further evidence for the lysosomal nature of palmitoyl-protein thioesterase function. Biochim. </plain></SENT>
<SENT sid="364" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="365" pm="."><plain>Acta 1583 35–44. 10.1016/S1388-1981(02)00158-0 <?supplied-pmid 12069847?>12069847 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="366" pm="."><plain>MaccarroneM.BattistaN.CentonzeD. (2007). The endocannabinoid pathway in Huntington’s disease: a comparison with other neurodegenerative diseases. Prog. </plain></SENT>
<SENT sid="367" pm="."><plain>Neurobiol. 81 349–379. 10.1016/j.pneurobio.2006.11.006 <?supplied-pmid 17276576?>17276576 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="368" pm="."><plain>MaccarroneM.GubelliniP.BariM.PicconiB.BattistaN.CentonzeD. (2003). Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. </plain></SENT>
<SENT sid="369" pm="."><plain>Neurochem. 85 1018–1025. 10.1046/j.1471-4159.2003.01759.x <?supplied-pmid 12716433?>12716433 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="370" pm="."><plain>MarquesA. </plain></SENT>
<SENT sid="371" pm="."><plain>R.AtenJ.OttenhoffR.van RoomenC. </plain></SENT>
<SENT sid="372" pm="."><plain>P.Herrera MoroD.ClaessenN. (2015). Reducing GBA2 activity ameliorates neuropathology in Niemann-Pick type C mice. PLoS One 10:e135889. 10.1371/journal.pone.0135889 <?supplied-pmid 26275242?>26275242 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="373" pm="."><plain>NietupskiJ. </plain></SENT>
<SENT sid="374" pm="."><plain>B.PachecoJ. </plain></SENT>
<SENT sid="375" pm="."><plain>J.ChuangW. </plain></SENT>
<SENT sid="376" pm="."><plain>L.MarateaK.LiL.FoleyJ. (2012). Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice. Mol. </plain></SENT>
<SENT sid="377" pm="."><plain>Genet. </plain></SENT>
<SENT sid="378" pm="."><plain>Metab. 105 621–628. 10.1016/j.ymgme.2012.01.020 <?supplied-pmid 22366055?>22366055 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="379" pm="."><plain>NomuraD. </plain></SENT>
<SENT sid="380" pm="."><plain>K.DixM. </plain></SENT>
<SENT sid="381" pm="."><plain>M.CravattB. </plain></SENT>
<SENT sid="382" pm="."><plain>F. (2010a). Activity-based protein profiling for biochemical pathway discovery in cancer. Nat. </plain></SENT>
<SENT sid="383" pm="."><plain>Rev. </plain></SENT>
<SENT sid="384" pm="."><plain>Cancer 10 630–638. 10.1038/nrc2901 <?supplied-pmid 20703252?>20703252 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="385" pm="."><plain>NomuraD. </plain></SENT>
<SENT sid="386" pm="."><plain>K.LongJ. </plain></SENT>
<SENT sid="387" pm="."><plain>Z.NiessenS.HooverH. </plain></SENT>
<SENT sid="388" pm="."><plain>S.NgS. </plain></SENT>
<SENT sid="389" pm="."><plain>W.CravattB. </plain></SENT>
<SENT sid="390" pm="."><plain>F. (2010b). Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140 49–61. 10.1016/j.cell.2009.11.027 <?supplied-pmid 20079333?>20079333 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="391" pm="."><plain>NomuraD. </plain></SENT>
<SENT sid="392" pm="."><plain>K.MorrisonB. </plain></SENT>
<SENT sid="393" pm="."><plain>E.BlankmanJ. </plain></SENT>
<SENT sid="394" pm="."><plain>L.LongJ. </plain></SENT>
<SENT sid="395" pm="."><plain>Z.KinseyS. </plain></SENT>
<SENT sid="396" pm="."><plain>G.MarcondesM. </plain></SENT>
<SENT sid="397" pm="."><plain>C. (2011). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334 809–814. 10.1126/science.1209200 <?supplied-pmid 22021672?>22021672 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="398" pm="."><plain>OgasawaraD.DengH.ViaderA.BaggelaarM. </plain></SENT>
<SENT sid="399" pm="."><plain>P.BremanA.den DulkH. (2016). Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition. Proc. </plain></SENT>
<SENT sid="400" pm="."><plain>Natl. </plain></SENT>
<SENT sid="401" pm="."><plain>Acad. </plain></SENT>
<SENT sid="402" pm="."><plain>Sci. </plain></SENT>
<SENT sid="403" pm="."><plain>U.S.A. 113 26–33. 10.1073/pnas.1522364112 <?supplied-pmid 26668358?>26668358 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="404" pm="."><plain>OguraY.ParsonsW. </plain></SENT>
<SENT sid="405" pm="."><plain>H.KamatS. </plain></SENT>
<SENT sid="406" pm="."><plain>S.CravattB. </plain></SENT>
<SENT sid="407" pm="."><plain>F. (2016). A calcium-dependent acyltransferase that produces N-acyl phosphatidylethanolamines. Nat. </plain></SENT>
<SENT sid="408" pm="."><plain>Chem. </plain></SENT>
<SENT sid="409" pm="."><plain>Biol. 12 669–671. 10.1038/nchembio.2127 <?supplied-pmid 27399000?>27399000 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="410" pm="."><plain>PanX.GrigoryevaL.SeyrantepeV.PengJ.KollmannK.TremblayJ. (2014). Serine carboxypeptidase SCPEP1 and cathepsin A play complementary roles in regulation of vasoconstriction via inactivation of endothelin-1. PLoS Genet. 10:e1004146. 10.1371/journal.pgen.1004146 <?supplied-pmid 24586188?>24586188 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="411" pm="."><plain>PanikashviliD.SimeonidouC.Ben-ShabatS.HanusL.BreuerA.MechoulamR. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413 527–531. 10.1038/35097089 <?supplied-pmid 11586361?>11586361 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="412" pm="."><plain>PetreraA.GassenhuberJ.RufS.GunasekaranD.EsserJ.ShahinianJ. </plain></SENT>
<SENT sid="413" pm="."><plain>H. (2016). Cathepsin A inhibition attenuates myocardial infarction-induced heart failure on the functional and proteomic levels. J. </plain></SENT>
<SENT sid="414" pm="."><plain>Transl. </plain></SENT>
<SENT sid="415" pm="."><plain>Med. 14:153. 10.1186/s12967-016-0907-8 <?supplied-pmid 27246731?>27246731 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="416" pm="."><plain>SchreuderH. </plain></SENT>
<SENT sid="417" pm="."><plain>A.LiesumA.KrollK.BöhnischB.BuningC.RufS. (2014). Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases. Biochem. </plain></SENT>
<SENT sid="418" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="419" pm="."><plain>Res. </plain></SENT>
<SENT sid="420" pm="."><plain>Commun. 445 451–456. 10.1016/j.bbrc.2014.02.014 <?supplied-pmid 24530914?>24530914 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="421" pm="."><plain>SchurmanL. </plain></SENT>
<SENT sid="422" pm="."><plain>D.LichtmanA. </plain></SENT>
<SENT sid="423" pm="."><plain>H. (2017). Endocannabinoids: a promising impact for traumatic brain injury. Front. </plain></SENT>
<SENT sid="424" pm="."><plain>Pharmacol. 8:69. 10.3389/fphar.2017.00069 <?supplied-pmid 28261100?>28261100 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="425" pm="."><plain>ScotterE. </plain></SENT>
<SENT sid="426" pm="."><plain>L.AboodM. </plain></SENT>
<SENT sid="427" pm="."><plain>E.GlassM. (2010). The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br. </plain></SENT>
<SENT sid="428" pm="."><plain>J. </plain></SENT>
<SENT sid="429" pm="."><plain>Pharmacol. 160 480–498. 10.1111/j.1476-5381.2010.00735.x <?supplied-pmid 20590559?>20590559 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="430" pm="."><plain>SeyrantepeV.HinekA.PengJ.FedjaevM.ErnestS.KadotaY. (2008). Enzymatic activity of lysosomal carboxypeptidase (cathepsin) a is required for proper elastic fiber formation and inactivation of endothelin-1. Circulation 117 1973–1981. 10.1161/CIRCULATIONAHA.107.733212 <?supplied-pmid 18391110?>18391110 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="431" pm="."><plain>SimonG. </plain></SENT>
<SENT sid="432" pm="."><plain>M.CravattB. </plain></SENT>
<SENT sid="433" pm="."><plain>F. (2010). Activity-based proteomics of enzyme superfamilies: serine hydrolases as a case study. J. </plain></SENT>
<SENT sid="434" pm="."><plain>Biol. </plain></SENT>
<SENT sid="435" pm="."><plain>Chem. 285 11051–11055. 10.1074/jbc.R109.097600 <?supplied-pmid 20147750?>20147750 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="436" pm="."><plain>TillnerJ.LehmannA.PaehlerT.LukacsZ.RufS.SadowskiT. (2016). Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects. Clin. </plain></SENT>
<SENT sid="437" pm="."><plain>Pharmacol. </plain></SENT>
<SENT sid="438" pm="."><plain>Drug Dev. 5 57–68. 10.1002/cpdd.201 <?supplied-pmid 27119579?>27119579 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="439" pm="."><plain>van der SteltM.Di MarzoV. (2005). Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med. 7 37–50. 10.1385/NMM:7:1-2:03716052037 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="440" pm="."><plain>VanierM.MillatG. (2003). Niemann-Pick disease type C. Clin. </plain></SENT>
<SENT sid="441" pm="."><plain>Genet. 64 269–281. 10.1034/j.1399-0004.2003.00147.x12974729 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="442" pm="."><plain>VizcaínoJ. </plain></SENT>
<SENT sid="443" pm="."><plain>A.CsordasA.del-ToroN.DianesJ. </plain></SENT>
<SENT sid="444" pm="."><plain>A.GrissJ.LavidasI. (2016). 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 44 D447–D456. 10.1093/nar/gkv1145 <?supplied-pmid 26527722?>26527722 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="445" pm="."><plain>WangR.BorazjaniA.MatthewsA. </plain></SENT>
<SENT sid="446" pm="."><plain>T.MangumL. </plain></SENT>
<SENT sid="447" pm="."><plain>C.EdelmannM. </plain></SENT>
<SENT sid="448" pm="."><plain>J.RossM. </plain></SENT>
<SENT sid="449" pm="."><plain>K. (2013). Identification of palmitoyl protein thioesterase 1 in human THP1 monocytes and macrophages and characterization of unique biochemical activities for this enzyme. Biochemistry 52 7559–7574. 10.1021/bi401138s <?supplied-pmid 24083319?>24083319 </plain></SENT>
</text></ref></ref-list></SecTag><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list id="DL1"><def-item><term>ABHD</term><def><p>α/β-hydrolase domain-containing protein</p></def></def-item><def-item><term>ABPP</term><def><p>activity-based protein profiling</p></def></def-item><def-item><term>AEA</term><def><p>anandamide</p></def></def-item><def-item><term>2-AG</term><def><p>2-arachidonoylglycerol</p></def></def-item><def-item><term>CB<sub>x</sub>R</term><def><p>cannabinoid type x receptor</p></def></def-item><def-item><term>CTSA</term><def><p>cathepsin A</p></def></def-item><def-item><term>DAGL</term><def><p>diacylglycerol lipase</p></def></def-item><def-item><term>ECS</term><def><p>endocannabinoid system</p></def></def-item><def-item><term>FAAH</term><def><p>fatty acid amide hydrolase</p></def></def-item><def-item><term>FP</term><def><p>fluorophosphonate</p></def></def-item><def-item><term>GBA2</term><def><p>non-lysosomal glucosylceramidase</p></def></def-item><def-item><term>MAGL</term><def><p>monoacylglycerol lipase</p></def></def-item><def-item><term>NAPE</term><def><p><italic>N</italic>-acylphospatidylethanolamine</p></def></def-item><def-item><term>NPC</term><def><p>Niemann-Pick type C</p></def></def-item><def-item><term>PLA2G4E</term><def><p>phospholipase A2 group 4E</p></def></def-item><def-item><term>PLD</term><def><p>phospholipase D</p></def></def-item><def-item><term>PPT1</term><def><p>palmitoyl-protein thioesterase 1</p></def></def-item><def-item><term>SCPEP1</term><def><p>retinoid-inducible serine carboxypeptidase</p></def></def-item><def-item><term>SDS-PAGE</term><def><p>sodium dodecyl sulfate polyacrylamide gel electrophoresis</p></def></def-item><def-item><term>THL</term><def><p>tetrahydrolipstatin</p></def></def-item></def-list></glossary></SecTag></back></article>
